William Blair Issues Pessimistic Estimate for LRMR Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities research analysts at William Blair lowered their Q1 2025 EPS estimates for Larimar Therapeutics in a research note issued to investors on Monday, March 24th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($0.46) for the quarter, down from their previous forecast of ($0.35). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.01) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.07) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

A number of other research firms have also commented on LRMR. HC Wainwright raised their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday. Robert W. Baird lowered their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday. Truist Financial began coverage on Larimar Therapeutics in a research note on Wednesday, January 29th. They issued a “buy” rating and a $18.00 price target for the company. Finally, Guggenheim restated a “buy” rating and set a $26.00 price objective on shares of Larimar Therapeutics in a research note on Tuesday. Eleven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Larimar Therapeutics has an average rating of “Buy” and a consensus price target of $20.22.

Larimar Therapeutics Stock Performance

LRMR opened at $2.38 on Thursday. The stock has a fifty day moving average of $3.10 and a 200-day moving average of $5.16. The company has a market capitalization of $151.54 million, a P/E ratio of -2.07 and a beta of 0.99. Larimar Therapeutics has a fifty-two week low of $2.19 and a fifty-two week high of $11.20.

Hedge Funds Weigh In On Larimar Therapeutics

Institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC boosted its stake in Larimar Therapeutics by 27.2% in the third quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company’s stock valued at $36,379,000 after buying an additional 1,189,467 shares in the last quarter. Blue Owl Capital Holdings LP boosted its stake in shares of Larimar Therapeutics by 11.7% in the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company’s stock valued at $18,007,000 after purchasing an additional 486,211 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Larimar Therapeutics by 23.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock valued at $8,127,000 after purchasing an additional 399,123 shares in the last quarter. Alyeska Investment Group L.P. grew its holdings in shares of Larimar Therapeutics by 38.6% during the 4th quarter. Alyeska Investment Group L.P. now owns 984,077 shares of the company’s stock valued at $3,808,000 after purchasing an additional 273,920 shares during the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in Larimar Therapeutics by 278.8% during the 4th quarter. Cubist Systematic Strategies LLC now owns 233,873 shares of the company’s stock worth $905,000 after purchasing an additional 172,131 shares in the last quarter. Institutional investors and hedge funds own 91.92% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.